Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialAxel Hauschild, Paul B. Chapman, Jean‐Jacques Grob et al.|The Lancet|2012Cited by 3k
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialAlexander Eggermont, B. Guillot, Nageatte Ibrahim et al.|The Lancet Oncology|2021Cited by 389
Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint TherapyKathrin Renner, Marina Kreutz, Christina Bruß et al.|Cell Reports|2019Cited by 297
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines CommitteeUlrich Keilholz, Olivier Michielin, P.A. Ascierto et al.|Annals of Oncology|2020Cited by 232
Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-upJoost H. van den Berg, John B.A.G. Haanen, Bianca Heemskerk et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 196